View Item 

Show simple item record

Effect of Longâ Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report
dc.contributor.authorWang, Hom‐lay
dc.contributor.authorWeber, Daniel
dc.contributor.authorMcCauley, Laurie K.
dc.date.accessioned2018-02-05T16:37:03Z
dc.date.available2018-02-05T16:37:03Z
dc.date.issued2007-03
dc.identifier.citationWang, Hom‐lay ; Weber, Daniel; McCauley, Laurie K. (2007). "Effect of Longâ Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report." Journal of Periodontology 78(3): 584-594.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/141603
dc.publisherAmerican Academy of Periodontology
dc.publisherWiley Periodicals, Inc.
dc.subject.otherFosamax
dc.subject.otherosteonecrosis
dc.subject.otherBisphosphonate
dc.subject.otherdental implants
dc.subject.otherwound healing
dc.titleEffect of Longâ Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Pathology, Medical School, University of Michigan.
dc.contributor.affiliationumDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/141603/1/jper0584.pdf
dc.identifier.doi10.1902/jop.2007.060239
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferenceFicarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123 â 1128.
dc.identifier.citedreferenceAugust M, Chung K, Chang Y, Glowacki J. Influence of estrogen status on endosseous implant osseointegration. J Oral Maxillofac Surg 2001; 59: 1285 â 1289.
dc.identifier.citedreferenceBamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580 â 8587.
dc.identifier.citedreferenceShlomi B, Levy Y, Kleinman S. Avascular necrosis of the jaw bone after bisphosphonate therapy (in Hebrew). Harefuah 2005; 144: 536 â 539, 599â 600.
dc.identifier.citedreferenceMigliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonateâ associated osteonecrosis of mandibular and maxillary bone. Cancer 2005; 104: 83 â 93.
dc.identifier.citedreferenceLackner H, Benesch M, Moser A, et al. Aseptic osteonecrosis in children and adolescents treated for hematoâ oncologic diseases: A 13â year longitudinal observational study. J Pediatr Hematol Oncol 2005; 27: 259 â 263.
dc.identifier.citedreferenceGralow J. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer. Clin Breast Cancer 2005; 5 ( Suppl. 2 ) S54 â S62.
dc.identifier.citedreferencePark Sâ H, Lee Kâ W, Oh Tâ J, Misch CE, Shotwell JL, Wang Hâ L. Effect of absorbable membranes on sandwich bone augmentation. Clin Oral Implants Res; in press.
dc.identifier.citedreferenceNeer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1â 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434 â 1441.
dc.identifier.citedreferenceSeeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001; 12: 281 â 283.
dc.identifier.citedreferenceDempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 2001; 16: 1846 â 1853.
dc.identifier.citedreferenceLindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the aminoâ terminal fragment of human parathyroid hormoneâ (1â 34): Kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993; 77: 1535 â 1539.
dc.identifier.citedreferenceLindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebralâ bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550 â 555.
dc.identifier.citedreferenceHock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 1992; 7: 65 â 72.
dc.identifier.citedreferenceLacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165 â 176.
dc.identifier.citedreferenceYasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisâ inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597 â 3602.
dc.identifier.citedreferenceMa YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH (1â 38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and geneâ associated bone formation. Endocrinology 2001; 142: 4047 â 4054.
dc.identifier.citedreferenceLocklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003; 89: 180 â 190.
dc.identifier.citedreferenceTam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 1982; 110: 506 â 512.
dc.identifier.citedreferenceArdine M, Generali D, Donadio M, et al. Could the longâ term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006; 17: 1336 â 1337.
dc.identifier.citedreferenceVinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996; 73: 1089 â 1095.
dc.identifier.citedreferenceBerruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A. Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates. J Urol 2001; 166: 2023 â 2031.
dc.identifier.citedreferenceAmerican Academy of Periodontology. AAP statement on bisphosphonates. Available at: http://www.perio.org/resourcesâ products/bisphosphonates.htm. Accessed May 25, 2006.
dc.identifier.citedreferenceFleisch H, Russell RG, Bisaz S, Casey P, Muhlbayer R. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 1968; ( Suppl. ) 10 â 10a.
dc.identifier.citedreferenceFleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications on calcium hemostasis. Nature 1966; 212: 901 â 903.
dc.identifier.citedreferenceFleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30 â 34.
dc.identifier.citedreferenceFrancis MD, Russell RG, Fleisch H. Disphosphonates inhibit formation of calcium phosphate crystals in vitro and pathologic calcifications in vivo. Science 1969; 165: 1264 â 1266.
dc.identifier.citedreferenceFleisch H, Russell RG, Francis MD. Disphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969; 165: 1262 â 1264.
dc.identifier.citedreferenceGreen J. Bisphosphonates: Preclinical review. Oncologist 2004; 9 ( Suppl. 4 ) 3 â 13.
dc.identifier.citedreferenceBenford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgerniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131 â 140.
dc.identifier.citedreferenceBergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231 â 241.
dc.identifier.citedreferenceLehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenineâ containing metabolite. Mol Pharmacol 2002; 61: 1255 â 1262.
dc.identifier.citedreferenceMcClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003; 32: 253 â 271.
dc.identifier.citedreferenceKatsuki H, Bloch K. Studies on the biosynthesis of ergosterols in yeast: Formation of methylated intermediates. J Biol Chem 1967; 242: 222 â 227.
dc.identifier.citedreferenceLynen F. Biosynthetic pathways from acetate to natural products. Pure Appl Chem 1967; 14: 137 â 167.
dc.identifier.citedreferenceMoran LA, Scrimgeour KG, Horton HR, Ochs RS, Rawn JD. Biochemistry, 2nd ed. Upper Saddle River, NJ: Prentice Hall; 1994: 852.
dc.identifier.citedreferenceWatanabe Y, Shiomi M, Tsujita Y, et al. Preventive effect of pravastatin sodium, a potent inhibitor of 3â hydroxyâ 3â methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 1988; 960: 294 â 302.
dc.identifier.citedreferenceGober HJ, Kistowska M, Angman L, et al. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163 â 168.
dc.identifier.citedreferenceLuckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycleâ containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structureâ activity relationships in J774 macrophages. J Bone Miner Res 1998; 13: 1668 â 1678.
dc.identifier.citedreferenceAlakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002; 70: 40 â 47.
dc.identifier.citedreferenceDunford JE, Thompson K, Coxon FP, et al. Structureâ activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogenâ containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235 â 242.
dc.identifier.citedreferenceMonkkonen H, Lehenkari PP, Kellinsalmi M, et al. A new mechanism of action for bisphosphonates: Appi dedicated cytotoxicity of Nâ BPs. In: Bone Workshops, Davos 2004. Abstracts from the Workshop: Frontiers of Skeletal Biology and Workshop: What is New in Bisphosphonates? Davos, Switzerland, March 20â 26, 2004. Bone 2004; 34 ( Suppl. 1 ) S66.
dc.identifier.citedreferenceSelander KS, Monkkonen J, Karhukorpi EK, Harkonen P, Hannuniemi R, Vannanen K. Characteristics of clodronateâ induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50: 1127 â 1138.
dc.identifier.citedreferenceConte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 ( Suppl. 4 ) 28 â 37.
dc.identifier.citedreferenceBounameaux HM, Schifferi J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous disphosphonates. Lancet 1983; 1: 471.
dc.identifier.citedreferenceShinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure relationships of various bisphosphonates. Calcif Tissue Int 1983; 35: 87 â 99.
dc.identifier.citedreferenceMarkowitz GS, Apple GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with highâ dose pamidronate. J Am Soc Nephrol 2001; 12: 1164 â 1172.
dc.identifier.citedreferenceRosen LS, Gordon D, Tchekmedyian S, et al. Zolendric acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, doubleâ blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150 â 3157.
dc.identifier.citedreferenceAtula S, Powles T, Paterson A, McCloskey E, Nevalainen J, Kanis J. Extended safety profile of oral clodronate after longâ term use in primary breast cancer patients. Drug Saf 2003; 26: 661 â 671.
dc.identifier.citedreferenceTanko LB, McClung M, Schimmer RC, Mahoney P, Christiansen C. The efficacy of 48â week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003; 32: 421 â 426.
dc.identifier.citedreferenceClowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 1117 â 1123.
dc.identifier.citedreferenceThakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006; 23: 51 â 56.
dc.identifier.citedreferenceMarx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115 â 1117.
dc.identifier.citedreferenceMarx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateâ induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567 â 1575.
dc.identifier.citedreferenceMigliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253 â 4254.
dc.identifier.citedreferenceRuggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527 â 534.
dc.identifier.citedreferenceBadros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945 â 952.
dc.identifier.citedreferenceHellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bisâ phossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63: 682 â 689.
dc.identifier.citedreferenceHansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates: Histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35: 155 â 160.
dc.identifier.citedreferenceWoo SB, Hellstein JW, Kalmar JR. Narrative review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753 â 761.
dc.identifier.citedreferenceMigliorati CA, Siegel MA, Elting LS. Bisphosphonateâ associated osteonecrosis: A longâ term complication of bisphosphonate treatment. Lancet Oncol 2006; 7: 508 â 514.
dc.identifier.citedreferenceStrewler GJ. Decimal pointâ osteoporosis therapy at the 10â year mark. N Engl J Med 2004; 350: 1172 â 1174.
dc.identifier.citedreferenceDando TM, Noble S. Onceâ monthly ibandronate. Treat Endocrinol 2005; 4: 381 â 387.
dc.identifier.citedreferenceEmkey R, Koltun W, Beusterien K, et al. Patient preference for onceâ monthly ibandronate versus onceâ weekly alendronate in a randomized, openâ label, crossâ over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895 â 1903.
dc.identifier.citedreferenceLeu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006; 38: 628 â 636.
dc.identifier.citedreferenceNancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006; 38: 617 â 627.
dc.identifier.citedreferenceOdvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294 â 1301.
dc.identifier.citedreferenceDao TT, Anderson JD, Zarb GA. Is osteoporosis a risk factor for osseointegration of dental implants? Int J Oral Maxillofac Implants 1993; 8: 137 â 144.
dc.identifier.citedreferenceSiris ES, Miller PD, Barrettâ Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815 â 2822.
dc.identifier.citedreferenceGadeleta SJ, Boskey AL, Paschalis E, et al. A physical, chemical, and mechanical study of lumbar vertebrae from normal, ovariectomized, and nandrolone decanoateâ treated cynomolgus monkeys ( Macaca fascicularis ). Bone 2000; 27: 541 â 550.
dc.identifier.citedreferenceFriberg B, Ekestubbe A, Mellstrom D, Sennerby L. BrÃ¥nemark implants and osteoporosis: A clinical exploratory study. Clin Implant Dent Relat Res 2001; 3: 50 â 56.
dc.identifier.citedreferenceMinsk L, Polson AM. Dental implant outcomes in postmenopausal women undergoing hormone replacement. Compend Contin Educ Dent 1998; 19: 859 â 862.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper0584.pdf
Size:
16.64MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.